Juraj Prejac

Hepatic and Pancreatobiliary Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Multidisciplinary Approach

Sanja Stojsavljević, Goran Poropat, Iva Skočilić, Petra Puz Britvic et autres

Parallel to the increased use of immune checkpoint inhibitors (ICIs), the incidence of immune-related adverse events (irAEs) is also increasing. Almost all organs can be affected by the immune-mediated response, including the liver, pancreas and biliary tract. Immune-Mediated Hepatitis is a common …

hr (code pays fourni par la source)

Shrinking Giants: On the Feasibility of Downsizing Hepatocellular Carcinoma with Immunotherapy Prior to Liver Transplantation

Juraj Prejac, Domina Kekez, Hana Lučev, Borna Ćutić et autres

Background/Objectives: Hepatocellular carcinoma (HCC) is a major cause of cancer-related morbidity and mortality, with incidence expected to increase. Liver transplantation is the most definitive curative option for early HCC, but many patients present beyond accepted transplant criteria, including the Milan criteria. Downstaging …

hr (code pays fourni par la source)

Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape

Andrej Belančić, Juraj Prejac, Marin Golčić, Gordan Adžić et autres

Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract and are primarily driven by activating mutations in KIT or PDGFRA. Although tyrosine kinase inhibitors (TKIs), particularly imatinib, have substantially improved outcomes, most patients with advanced disease …

hr (code pays fourni par la source)

Expert opinion on treatment patterns in metastatic colorectal cancer management in Eastern Europe

László Torday, Alinta Hegmane, Biljana Kukić, Edita Baltruškevičienė et autres

Colorectal cancer (CRC) is the third most prevalent malignancy globally and the second leading cause of cancer-related mortality. Approximately 15%-30% of patients are diagnosed with metastatic CRC (mCRC), and despite increasing survival rates, mCRC remains fatal. There are notable variations in the …

hu, gb, lv, rs, lt, ro, hr, si, me, bg, ba, jp (code pays fourni par la source)

Immune-Mediated Colitis Induced by Immune Checkpoint Inhibitors: Pathophysiology, Clinical Management, and the Emerging Role of Fecal Microbiota Transplantation

Željka Belošić Halle, Vedran Tomasic, Alen Biscanin, Petra Cacic et autres

BACKGROUND/OBJECTIVES: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various malignancies, but their use is frequently accompanied by immune-related adverse events, among which immune-mediated colitis (IMC) represents one of the most common and clinically significant gastrointestinal toxicities. IMC may lead to …

hr (code pays fourni par la source)

Serial assessment of inflammatory biomarkers as a prognostic factor for first-line treatment outcomes in patients with metastatic colorectal cancer: single-center retrospective study

Nikša Librenjak, Gordan Adžić, Domina Kekez, Irma Goršić et autres

Background: Metastatic colorectal cancer (mCRC) is a major cause of cancer-related mortality, with limited curative options despite advances in targeted therapies. Reliable prognostic biomarkers are needed to guide treatment. Inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) …

hr (code pays fourni par la source)

Patients with hepatocellular carcinoma achieving a complete response to sorafenib: Three case reports and review of literature

Hana Lučev, Gordan Adžić, Stjepko Pleština, Juraj Prejac

BACKGROUND: Sorafenib has been the conventional treatment for advanced hepatocellular carcinoma (HCC) since 2008. While radiological complete responses are extremely rare, improved supportive care and multidisciplinary approaches in clinical practice may explain the recent increase in case reports and retrospective series documenting …

hr (code pays fourni par la source)

Hepatobiliary cancers

Juraj Prejac

hr (code pays fourni par la source)

Phase angle as a prognostic biomarker in metastatic colorectal cancer: A prospective trial

Domina Kekez, Juraj Prejac, Gordan Adžić, Nikša Librenjak et autres

BACKGROUND: Colorectal cancer (CRC) represents a major global public health issue, ranking as the third most common cancer worldwide. Given the substantial prevalence of CRC, there is a critical need to identify precise prognostic and predictive biomarker tools for better treatment outcomes. …

hr (code pays fourni par la source)

List of contributors

Ashique Ahamed, İmatullah Akyar, Ahmad Samir Alfaar, Andrej Belančić et autres

Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy

Bernhard Scheiner, Beodeul KANG, Lorenz Balcar, Iuliana‐Pompilia Radu et autres

BACKGROUND AND AIMS: The outcome of patients with HCC who achieved complete response (CR) to immune-checkpoint inhibitor (ICI)-based systemic therapies is unclear. APPROACH AND RESULTS: Retrospective study of patients with HCC who had CR according to modified Response Evaluation Criteria in Solid …

at, kr, ch, de, hr, cn, be, it, gb, jp, tw, us, ca, fr (code pays fourni par la source)

Neurološki simptom kao prvi znak kolorektalnog karcinoma

Ivo Dilber, Ivana Radovčić Gauta, Lana Jajac Bručić, Iva Škifić et autres

Aim: To present a rare case of a patient with an isolated brain metastasis from colorectal carcinoma in whom an extensive diagnostic workup failed to identify the primary tumour. Case report: A 73-year-old female patient was admitted to the Neurology Department due …

hr (code pays fourni par la source)